SPY421.97-0.14 -0.03%
DIA338.65-2.11 -0.62%
IXIC14,161.35+121.67 0.87%

Intra-Cellular Therapies Q1 EPS $(0.65) Beats $(0.80) Estimate, Sales $15.88M Miss $16.50M Estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.80) by 18.75 percent. This is a 10.96 percent increase over losses of $(0.73) per

05/10/2021 07:32
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.80) by 18.75 percent. This is a 10.96 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $15.88 million which missed the analyst consensus estimate of $16.50 million by 3.77 percent. This is a 1.37K percent increase over sales of $1.08 million the same period last year.